BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SY, Helman LJ. Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res 2009;152:517-28. [PMID: 20213413 DOI: 10.1007/978-1-4419-0284-9_31] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Naviglio S. The possible use of inorganic phosphate in osteosarcoma therapy. Future Oncol. 2013;9:1249-1251. [PMID: 23654203 DOI: 10.2217/fon.13.95] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
2 Rivera-Valentin RK, Zhu L, Hughes DP. Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy. Paediatr Drugs 2015;17:257-71. [PMID: 26002157 DOI: 10.1007/s40272-015-0134-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
3 Shang J, Fan X, Liu H. The role of mechano-growth factor E peptide in the regulation of osteosarcoma. Oncol Lett 2015;10:697-704. [PMID: 26622556 DOI: 10.3892/ol.2015.3339] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Xiong S, Xiong G, Li Z, Jiang Q, Yin J, Yin T, Zheng H. Gold nanoparticle-based nanoprobes with enhanced tumor targeting and photothermal/photodynamic response for therapy of osteosarcoma. Nanotechnology 2021;32:155102. [PMID: 33395672 DOI: 10.1088/1361-6528/abd816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer 2014;14:681. [PMID: 25236161 DOI: 10.1186/1471-2407-14-681] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
6 Zhang W, Ding ML, Zhang JN, Qiu JR, Shen YH, Ding XY, Deng LF, Zhang WB, Zhu J. mTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma. Sci Rep 2015;5:9604. [PMID: 25853231 DOI: 10.1038/srep09604] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
7 Yin JQ, Wen L, Wu LC, Gao ZH, Huang G, Wang J, Zou CY, Tan PX, Yong BC, Jia Q, Shen JN. The glycogen synthase kinase-3β/nuclear factor-kappa B pathway is involved in cinobufagin-induced apoptosis in cultured osteosarcoma cells. Toxicol Lett 2013;218:129-36. [PMID: 23164673 DOI: 10.1016/j.toxlet.2012.11.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
8 Gonzalez AL, Cates JM. Osteosarcoma: Differential Diagnostic Considerations. Surg Pathol Clin 2012;5:117-46. [PMID: 26837918 DOI: 10.1016/j.path.2011.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Sane S, Abdullah A, Nelson ME, Wang H, Chauhan SC, Newton SS, Rezvani K. Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy. Cell Stress Chaperones 2016;21:313-26. [PMID: 26634371 DOI: 10.1007/s12192-015-0661-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
10 Liu J, Wu J, Zhou L, Pan C, Zhou Y, Du W, Chen JM, Zhu X, Shen J, Chen S, Liu RY, Huang W. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. Oncotarget 2015;6:21341-52. [PMID: 26050198 DOI: 10.18632/oncotarget.4179] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
11 Spina A, Sorvillo L, Chiosi E, Esposito A, Di Maiolo F, Sapio L, Caraglia M, Naviglio S. Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells. Oncol Rep. 2013;29:1689-1696. [PMID: 23446517 DOI: 10.3892/or.2013.2306] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
12 Shan H, Li K, Zhao D, Chi C, Tan Q, Wang X, Yu J, Piao M. Locally Controlled Release of Methotrexate and Alendronate by Thermo-Sensitive Hydrogels for Synergistic Inhibition of Osteosarcoma Progression. Front Pharmacol 2020;11:573. [PMID: 32508628 DOI: 10.3389/fphar.2020.00573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Younis JA, Al Antably IM, Zamzam M, Salem HT, Zaki EM, Hassanian OA. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in prediction of response to neoadjuvant chemotherapy in pediatric osteosarcoma. World J Nucl Med 2019;18:378-88. [PMID: 31933554 DOI: 10.4103/wjnm.WJNM_52_18] [Reference Citation Analysis]
14 Chauhan A, Joshi GR, Chopra BK, Ganguly M, Reddy GR. Limb salvage surgery in bone tumors: a retrospective study of 50 cases in a single center. Indian J Surg Oncol 2013;4:248-54. [PMID: 24426731 DOI: 10.1007/s13193-013-0229-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
15 Vangala N, Uppin SG, Rao KN, Chandrasekhar P, Gundeti S. Prognostic Significance of Clinical and Post-Neoadjuvant Chemotherapy Associated Histomorphological Parameters in Osteosarcoma: A Retrospective Study from a Tertiary Care Center. Indian J Med Paediatr Oncol 2021;42:547-53. [DOI: 10.1055/s-0041-1740113] [Reference Citation Analysis]
16 Spina A, Sorvillo L, Di Maiolo F, Esposito A, D’Auria R, Di Gesto D, Chiosi E, Naviglio S. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway. J Cell Physiol. 2013;228:198-206. [PMID: 22674530 DOI: 10.1002/jcp.24124] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
17 Zhao L, Bi D, Qi X, Guo Y, Yue F, Wang X, Han M. Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy. Nanotechnology 2019;30:255101. [PMID: 30736019 DOI: 10.1088/1361-6528/ab055f] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
18 Huang ST, Huang CC, Huang WL, Lin TK, Liao PL, Wang PW, Liou CW, Chuang JH. Tanshinone IIA induces intrinsic apoptosis in osteosarcoma cells both in vivo and in vitro associated with mitochondrial dysfunction. Sci Rep 2017;7:40382. [PMID: 28106052 DOI: 10.1038/srep40382] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
19 Li KT, Chen Q, Wang DW, Duan QQ, Tian S, He JW, Ou YS, Bai DQ. Mitochondrial pathway and endoplasmic reticulum stress participate in the photosensitizing effectiveness of AE-PDT in MG63 cells. Cancer Med. 2016;5:3186-3193. [PMID: 27700017 DOI: 10.1002/cam4.895] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
20 Ye S, Zhang J, Shen J, Gao Y, Li Y, Choy E, Cote G, Harmon D, Mankin H, Gray NS, Hornicek FJ, Duan Z. NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. Br J Pharmacol 2016;173:613-26. [PMID: 26603906 DOI: 10.1111/bph.13395] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
21 Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int 2011;35:569-74. [PMID: 21143201 DOI: 10.1042/CBI20100431] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]